Wag! Group (PET) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue declined 6% year-over-year to $18.7 million, while net loss narrowed to $2.3 million from $3.9 million, and adjusted EBITDA reached a record $1.6 million, driven by reduced marketing spend and operational efficiency.
Adjusted EBITDA margin improved to 8.8% from 0.5% a year ago, and net loss margin improved to (12.1)% from (19.5)% year-over-year.
Platform participants decreased 15% year-over-year to 467,000, but revenue per user increased due to a focus on higher quality customers and upsell/cross-sell initiatives.
Strategic priorities include building best-in-class software for premium pet households, expanding via product innovation, partnerships, and M&A, and leveraging the veterinary channel.
The company completed a public offering in July 2024, raising $8.6 million to address liquidity needs and pay down debt.
Financial highlights
Q2 2024 revenue: $18.7 million, down 6% year-over-year; wellness $11.5M, services $5.6M, pet food/treats $1.5M.
Adjusted EBITDA: $1.6 million, up from $0.1 million a year ago.
Net loss for Q2 2024 was $2.3 million, improved from $3.9 million a year ago.
Cash and cash equivalents at quarter end were $9.2 million, with $26.3 million in total debt outstanding.
Net cash used in operating activities was $2.0 million for the first half, down from $2.3 million in 2023.
Outlook and guidance
2024 revenue guidance reiterated at $92–$102 million, representing 10–22% growth over 2023.
2024 adjusted EBITDA guidance: $4–$8 million (4–8% margin), with positive free cash flow expected in H2 2024.
Q3 2024 guidance: revenue $20–$24 million, adjusted EBITDA $1.5–$2.5 million.
Management expects continued operating losses as investments in business growth persist.
Ongoing efforts to refinance debt and improve liquidity, but no assurance of success.
Latest events from Wag! Group
- Q3 revenue fell 39% with deepening losses, but Wellness rebounded and debt reduction continues.PET
Q3 202414 Jan 2026 - Q4 rebounded with 17%+ sequential growth; 2025 revenue guided at $84–$88 million.PET
Q4 202426 Dec 2025 - Q1 2025 revenue fell 34.7%, net loss widened, and liquidity risks persist despite new partnerships.PET
Q1 202527 Nov 2025 - Chapter 11 filing, revenue drop, delisting, and asset sale mark a critical restructuring phase.PET
Q2 20257 Aug 2025